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Abstract
Background:  Following resection of liver metastases from colorectal cancer, 5-year survivals are
reportedly 30 – 39%. It can be assumed that this clinical situation represents systemic disease. Therefore,
it is postulated that systemic chemotherapy would improve outcomes, particularly in those whose disease
is sensitive to the agents administered. One potential advantage of neoadjuvant chemotherapy is that it
provides in vivo chemosensitivity data. Response to neoadjuvant chemotherapy could therefore guide
adjuvant chemotherapy following resection of liver metastases from colorectal cancer.
Methods and design: This is a prospective Phase II evaluation of outcomes in patients with potentially
resectable liver metastases. Patients will receive neoadjuvant chemotherapy and will undergo resection.
Postoperative chemotherapy will be directed by the degree of response to preoperative chemotherapy.
All patients with Stage IV colorectal adenocarcinoma isolated to the liver that have disease that is amenable
to complete ablation by resection, radiofrequency ablation, and/or cryoablation will be candidates for the
trial. Patients will receive CPT-11 180 mg/m2 IV (over 90 minutes) on day 1 with 5-FU 400 mg/m2 bolus
and 600 mg/m2 by 22 hour infusion and calcium folinate 200 mg/m2 on days 1 and 2, every 2 weeks.
Altogether, six cycles of chemotherapy will be administered. Patients will then undergo resection and/or
radiofrequency ablation. Patients who had stable disease or a clinical response with preoperative
chemotherapy will receive an additional 12 cycles of CPT-11 180 mg/m2 IV (over 90 minutes) on day 1
with 5-FU 400 mg/m2 bolus and 600 mg/m2 by 22 hour infusion and calcium folinate 200 mg/m2 on days 1
and 2 (given every 2 weeks). Patients with resectable disease who had progressive disease during
neoadjuvant chemotherapy will receive best supportive care or an alternative agent, at the discretion of
the treating physician. Those patients who are not rendered free of disease following the neoadjuvant
chemotherapy and surgery will receive best supportive care or an alternative agent, at the discretion of
the treating physician. The primary endpoint of the study is disease-free survival. Secondary endpoints
include overall survival, safety and feasibility, response to chemotherapy, and quality of life.
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Background
Colorectal cancers are the third most common cause of
cancer death in North America. The liver is the most com-
mon site of metastasis. In patients with resectable liver
metastases, there is a good probability of long-term sur-
vival and even cure [1]. Untreated liver metastases are
almost uniformly fatal within 5 years of diagnosis and
median survival of patients with technically resectable
liver lesions who do not undergo surgery is about 14.2
months [2]. There are no good data concerning survival of
patients with resectable liver metastases who receive sys-
temic chemotherapy and do not undergo resection. On
the other hand, following resection, median survival is 19
– 30 months and 5-year survivals are reportedly 30 – 39%
[3].
Fluoropyrimidines such as 5-fluorouracil (5-FU) and 5-
fluoro-2'-deoxyuridine (FUDR) are among the most active
chemotherapeutic agents for the treatment of colorectal
adenocarcinoma. These agents are used as adjuvant ther-
apy following resection of the primary tumor or as pri-
mary therapy for control of unresectable metastases. In
general, the response rate for metastases from colorectal
cancer to fluoropyrimidine chemotherapy is 17–23%; a
higher likelihood of response can be expected with con-
comitant leucovorin [4].
The value of adjuvant fluoropyrimidine therapy following
resection of liver metastases has not been well studied.
However, a recent study from Memorial Sloan-Kettering
did demonstrate improved survival at two years in
patients who received FUDR via a hepatic arterial pump in
addition to systemic 5-FU compared to patients who
received systemic 5-FU alone [5]. These early results might
suggest an important role for regional chemotherapy in
these patients, but there are several potential problems
with this approach. The most important issue is the com-
plication rate associated with insertion of a hepatic arte-
rial pump. A major surgical procedure is necessary;
hepatic arterial chemotherapy is associated with hepatic
toxicity; and complications such as hepatic arterial throm-
bosis, infection and pump failure are not infrequent.
Therefore, while survival at two years appears to be
improved, problems associated with the intraarterial
administration of chemotherapy may have very real con-
sequences in some individuals in the short term. The
pumps are also prohibitively expensive. Therefore, identi-
fication of a strategy of equal efficacy using systemic
chemotherapy is desirable on a fiscal front. Finally, the
regimen described by the Sloan-Kettering group utilizes
two fluoropyrimidines. As a proportion of patients are
resistant to this group of antineoplastic agents [6,7], one
might anticipate some significant limitations with this
drug combination.
Because insufficient inhibition of thymidylate synthase
may be an important mechanism of resistance to fluoro-
pyrimidines [6-9], antineoplastic agents that operate by a
different mechanism are most likely to be useful in com-
bination. CPT-11 (irinotecan) has demonstrated signifi-
cant activity against colorectal adenocarcinoma [10,11].
CPT-11 inhibits the nuclear enzyme DNA-topoisomerase,
leading to lethal accumulation of single-strand DNA
breaks in the cell, a distinctly different mechanism of
action than the fluoropyrimidines. Two randomized trials
showed that second-line CPT-11 in patients with meta-
static colorectal cancer improved length and quality of life
compared to best supportive care [12] as well as alterna-
tive fluoropyrimidine-based regimens [13]. The combina-
tion of CPT-11 with 5-FU/LV is therefore justified because
they have distinctly different mechanisms of action and
because each agent has significant activity in metastatic
colorectal cancer.
Saltz and coworkers reported a randomized trial in which
a combination of 5-FU, LV and CPT-11 gave superior
results to 5-FU and LV or CPT-11 alone, when used as
first-line therapy for patients with metastatic colorectal
cancer [14]. Using this regimen, an objective response rate
of 39% was seen, the median survival was 14.8 months,
and quality of life was not compromised. These results
demonstrated the importance of combining CPT-11 with
fluoropyrimidines. Moreover, the regimen described by
this group represents an excellent potential alternative to
intrahepatic chemotherapy, in patients who have liver
metastases amenable to resection.
Douillard similarly reported on the combination of CPT-
11 with infusional 5-FU in a randomized trial of 387 pre-
viously untreated patients [15]. Again, the response rates
were significantly better than those who received 5-FU
alone (49% vs. 31%, P < 0.001). Moreover, time to pro-
gression was longer (6.7 vs 4.4 months, P < 0.001) and
overall survival was improved (17.4 vs. 14.1, P = 0.031) in
the CPT-11 containing arm. Although responses and sur-
vival benefits did not differ significantly between Saltz
and Douillard regimens, the Douillard program with infu-
sional 5-FU appeared to have a lower incidence of nausea/
vomiting and neutropenia. Diarrhea is a common side
effect of CPT-11 containing regimens. Grade 3 or 4
diarrhea was observed at similar rates with the Saltz and
Douillard protocols (22% vs. 24%, respectively).
The application of chemotherapy on a neoadjuvant basis
has a number of potential advantages in patients with
resectable liver metastases. The degree of response gives
information on the in vivo chemosensitivity of the
tumor(s). This may help to determine the appropriateness
of further treatments with the same chemotherapeutic
agents after resection. In nonresponders, the adverseBMC Cancer 2004, 4:32 http://www.biomedcentral.com/1471-2407/4/32
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effects of these agents are avoided and alternative agents
can be considered. Administration of chemotherapy on a
neoadjuvant basis may also enable selection of candidates
for resection. That is, patients who develop extrahepatic
foci of disease during a short course of chemotherapy
likely were unsuitable for resection in the first place.
Finally, in some instances, neoadjuvant chemotherapy
may enhance resectability. Reduction of tumor volume
may limit the amount of liver that will need to be
removed to accomplish eradication of disease [16-18].
Methods and design
Trial objectives
The general aim of this protocol is to determine the effi-
cacy of neoadjuvant chemotherapy for patients with ablat-
able liver metastases from colorectal cancer in reducing
recurrence rate. Response to the chemotherapy regimen
will constitute an in vivo chemosensitivity test, and this
will guide adjuvant chemotherapy following resection of
liver metastases from colorectal cancer. The primary
objective is to evaluate disease-free survival following
neoadjuvant 5-FU, LV and CPT-11, resection/ablation,
and post-operative chemotherapy. Secondary objectives
include: a) to document safety; b) to assess the feasibility;
c) to evaluate overall survival; d) to determine the objec-
tive response rate of liver metastases; and e) to assess qual-
ity of life during and after this multimodality regimen.
Endpoints
The primary endpoint is overall disease-free (DFS) sur-
vival (including intrahepatic and extrahepatic recur-
rences). Secondary endpoints are as follows: a) safety (as
measured by adverse events, toxicity from chemotherapy,
and perioperative morbidity and mortality); b) feasibility
(defined as tolerance of the complete course of preopera-
tive chemotherapy in >90% of patients and completion of
postoperative chemotherapy in addition to preoperative
chemotherapy and surgery in >75% of patients); c) overall
survival; d) tumor response to chemotherapy; e) quality
of life; and f) histologic pattern of response.
Inclusion criteria
a) All patients with Stage IV colorectal adenocarcinoma
isolated to the liver. b) At least one measurable lesion by
CT or MRI. c) Metastases are technically completely resect-
able or amenable to complete ablation by cryoablation
and/or radiofrequency ablation. d) Karnofsky perform-
ance score > 70. e) Adequate bone marrow function: WBC
> 3000/mm3, absolute neutrophil count > 1500/mm3,
platelet count > 100,000/mm3. f) Adequate hepatic func-
tion: bilirubin ≤ 1.5 × ULN, AST/ALR ≤ 3 × ULN g) Ade-
quate renal function: serum creatinine ≤ 150 µmol/L or
calculated creatinine clearance ≥ 60 ml/min. h) Age 18 –
70 years, inclusive. i) Men and women of reproductive age
must agree to use an effective contraceptive method while
on study. j) Women of childbearing age must have had a
negative pregnancy test prior to registration. h) Informed
written consent has been obtained. History, physical
examination, chest X-ray, CT scan of the abdomen and/or
MRI of the liver, and biopsy confirmation of at least one
of the liver metastases will be required to confirm eligibil-
ity of the patient for this trial.
Exclusion criteria
a) Primary tumor not controlled by locoregional treat-
ments. b) Bilateral portal vein and/or hepatic artery
involvement. c) Previous chemotherapy directed at treat-
ment of metastatic colorectal cancer. (Note: Patients with
previous exposure to adjuvant chemotherapy for treat-
ment of the primary tumor are not excluded if the comple-
tion of the adjuvant therapy was greater than 1 year prior
to enrollment.) d) Underlying acute or chronic liver dis-
ease. e) Patients with known Gilbert's disease. f) Patients
receiving phenytoin or phenobarbital prophylaxis. g)
Presence of any concurrent medical or psychiatric condi-
tions that serve as a contraindication to surgery or chem-
otherapy. h) Pregnancy, lactation or refusal of female
patients of child-bearing age to submit to a pregnancy test.
i) Malignancy other than basal cell carcinoma or squa-
mous cell carcinoma of the skin within the preceding 5
years. j) Use of another investigational medication con-
currently or within 4 months of enrollment.
Trial design
This is a prospective phase II trial. The trial is uncontrolled
and nonrandomized. It began as a single-center trial but it
has expanded to a multicenter trial. Patients who are
chemotherapy-naive will be analyzed separately from
those previously exposed to chemotherapy; each of these
groups will be compared to historical controls who under-
went resection of liver metastases without receiving adju-
vant chemotherapy. Subgroups to be analyzed include
those patients who are non-responders to neoadjuvant
chemotherapy and patients who are responders to neoad-
juvant chemotherapy.
The study is an open label study, where all patients receive
neoadjuvant chemotherapy. Following resection, the type
of chemotherapy administered will be determined sec-
ondary to evaluation of the response to preoperative
chemotherapy. Patients may discontinue from the study
voluntarily or be discontinued by the investigator.
Patients who drop out of the study for any reason will not
be replaced.
Schedule of events
The schema summarizing the treatment plan is depicted
in Figure 1. Prior to initiating the protocol, a preliminary
evaluation as detailed below will be performed. Patients
will receive three cycles of chemotherapy (5-FU/LV/CPT-BMC Cancer 2004, 4:32 http://www.biomedcentral.com/1471-2407/4/32
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Schema of protocol Figure 1
Schema of protocol.
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11) and will then be assessed for progression of disease. If
progression is noted, they will be immediately assessed
for surgery. If stable or responsive disease is observed,
patients will receive another three cycles of chemotherapy.
Surgery will be performed at the completion of this 12-
week period of neoadjuvant chemotherapy. Following
chemotherapy, patients will receive another course of
chemotherapy for 24 weeks. They will receive 5-FU/LV/
CPT-11 if they had a clinical response or stable disease
during preoperative chemotherapy. In patients whose dis-
ease progressed during administration of 5-FU/LV/CPT-
11 in the preoperative period, an alternative agent (eg:
capecitibine, oxaliplatin) or best supportive care (BSC)
will be offered, at the discretion of the treating physician.
Initial, perioperative and periodic evaluations
Typically, patients will be identified during routine fol-
low-up surveillance, after treatment of the primary color-
ectal cancer. These patients will undergo a biopsy of a
single liver tumor as part of their initial assessment, as
well as the other investigations described in Table 1 (see
Additional file 1). Patients with metachronous metastases
12 months or more after resection of the primary lesion
will require a colonoscopy. Other patients will be identi-
fied at the time of surgery, during treatment of their pri-
mary colorectal cancer. These patients will not require a
subsequent biopsy, if a biopsy of a liver tumor has been
obtained.
The minimal radiological evaluation of the patient will
consist of an abdominal CT scan at the time of initial
assessment. A MRI scan of the liver will also be desirable,
although this will not be mandatory. After the chemother-
apy and just prior to the planned surgery, an abdominal
CT will be repeated; a repeat MRI is suggested, but is not
mandatory. In the interval after the first course of chemo-
therapy, a CT will be required, to ensure that disease pro-
gression has not occurred.
Initial (baseline) history and physical examination, as
well as baseline hematology and biochemistry must be
performed within 14 days of initiation of neoadjuvant
chemotherapy. CT and/or MRI must have been done
within 28 days of initiation of neoadjuvant
chemotherapy.
Perioperative parameters
Intraoperative events and findings will be recorded in the
usual way in the operative note. Blood loss, operating
time, and blood transfusions will be recorded. The surgi-
cal team will monitor for complications in the usual man-
ner and any complications will be treated appropriately.
Duration of hospital stay, complications, and mortalities
will be recorded.
Quality of life
Quality of life will be monitored using the Functional
Assessment of Cancer Therapy (FACT-C) Scale. Quality of
life will be assessed at study commencement, and at the
intervals described in Table 1 (see Additional file 1). Per-
mission has been granted by the Center on Outcomes
Research and Education to use the FACT-C subscale for
this trial.
Treatment schedule
Neoadjuvant chemotherapy
The goal is to administer chemotherapy for up to 12
weeks in the preoperative period. All patients will receive
CPT-11 180 mg/m2 on day 1 with 5-FU 400 mg/m2 bolus
and 600 mg/m2 by 22 hour infusion and calcium folinate
200 mg/m2 on days 1 and 2. This will be given every 2
weeks for 6 cycles (12 weeks total). At 6 – 8 weeks, the
clinical response will be assessed by abdominal CT scan
and the degree of response will dictate whether the
remaining three cycles of chemotherapy are given.
Management of patients with responsive, stable and progressive 
disease at the 6 – 8 week interval
If progressive disease is observed at the 6 – 8 week interval
as assessed by CT, neoadjuvant chemotherapy will be
stopped. Subsequent patient management will depend
upon whether the tumor is operable or inoperable. If the
disease is still resectable or ablatable, the patient will
undergo operation. If the disease is no longer amenable to
resection or ablation, the patient will be treated with BSC,
as detailed below.
Patients with stable or responsive disease will complete
their chemotherapy to week #12 (a total of six cycles),
then undergo surgery as per protocol. Patients who dem-
onstrate complete clinical disappearance of disease at any
time during the administration of preoperative chemo-
therapy will continue to receive the complete course of
preoperative chemotherapy. Hepatic resection will pro-
ceed as planned and will include the segment(s) previ-
ously involved with tumor. In the case of a complete
response, radiofrequency ablation and cryoablation will
not be utilized.
Surgery: hepatic resection or ablation
Once extrahepatic metastases have been ruled out and if
hepatic functional reserve is sufficient, a laparotomy will
be performed. Intraoperative ultrasound will be per-
formed to assess for previously undetected lesions and to
aid in the final assessment for resectability. Any suspicious
lesions encountered will be biopsied to rule out extrahe-
patic disease. Extrahepatic disease precludes further sur-
gery. Any enlarged lymph nodes in the periportal area will
be submitted separately for examination. Micrometastases
contained in periportal nodes are not a contraindicationBMC Cancer 2004, 4:32 http://www.biomedcentral.com/1471-2407/4/32
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to resection. The extent of hepatic resection – anatomic
and nonanatomic – will be determined by the operating
surgeon. A resection margin > 1 cm will be the goal. If
radiofrequency ablation or cryoablation are used, the goal
is to ablate the entire lesion plus a rim of normal tissue, if
anatomically feasible. In selected circumstances (eg: mul-
tiple bilobar metastases), radiofrequency ablation may be
administered percutaneously, at an interval, prior to resec-
tion. The exact sequence and the method of ablation will
be determined by the operating surgeon.
Non-resective ablation
In some patients, especially those with comorbidities that
prohibit a formal hepatic resection, radiofrequency abla-
tion may be preferable instead of or in addition to resec-
tion. In such patients, radiofreqency ablation will be
administered percutaneously or during a laparotomy,
depending on technical circumstances. The LeVeen probe
will be guided under ultrasound or CT guidance and the
entire lesion will be ablated. The endpoint of ablation will
be marked by the sudden increase in impedance.
Management of patients with residual disease after surgery
Completeness of resection is defined below. If there is no
evidence of residual disease, therapy will be continued as
per protocol. If there is evidence of residual disease fol-
lowing resection or ablation, the patient will be classified
as an event for DFS and will be treated with postoperative
5-FU/LV/CPT-11 or best supportive care, as directed by
the response to neoadjuvant chemotherapy.
Adjuvant chemotherapy
Adjuvant chemotherapy will be administered beginning
at 21 – 72 days after surgery. All patients with stable and
responsive disease following chemotherapy who undergo
liver resection or ablation will receive 12 additional cycles
of CPT-11 (180 mg/m2 on day 1) with 5-FU (400 mg/m2
bolus and 600 mg/m2 by 22 hour infusion) and calcium
folinate (20 mg/m2 on days 1 and 2) every 2 weeks (for a
total of 24 weeks). Patients with resectable disease who
had progressive disease during neoadjuvant chemother-
apy will be offered an alternative agent or BSC, at the dis-
cretion of the treating physician. Those patients who are
not rendered free of disease following the neoadjuvant
chemotherapy and surgery will receive palliative therapy
as outlined below.
Palliative therapy
Patients who progress to a state of nonresectability, or
who have gross residual disease following surgery will be
offered the following options, at the discretion of the
treating physician: a) symptomatic measures only (BSC);
b) second-line chemotherapy (eg: capecitibine, oxalipla-
tin); c) another study drug.
Assessment of efficacy and safety
Definitions of response to neoadjuvant chemotherapy
The degree of response to neoadjuvant chemotherapy will
be assessed by either CT scan or MRI scan, using the
RECIST guidelines [19]. In assessing response, the same
radiologic modality (ie: CT or MRI) that was utilized to
estimate extent of intrahepatic disease before chemother-
apy will be utilized to estimate extent of disease after
chemotherapy. Up to 5 "target" lesions will be identified
and these are selected on the basis of their size (ie: those
with the longest diameter). Baseline evaluation will con-
sist of determination of the sum of the longest diameters
of the target lesions, measured in millimeters. "Nontar-
get" lesions will also be enumerated and followed. Radio-
logic response of all lesions seen on MRI will be correlated
with findings on surgical pathology. The definitions of
response are described below.
Complete response (CR)
A complete response is the complete disappearance of all
target lesions and nontarget lesions, the absence of any
new lesions, the absence of disease-related symptoms,
and no evidence of non-evaluable disease (including
tumor markers and other laboratory values). This must be
confirmed by the absence of any microscopic residual via-
ble tumor in the resected specimen. A complete response
will not be assigned if any viable cells are present in the
resection specimen, regardless of the radiologic
appearance.
Partial response (PR)
A partial clinical response is a reduction in the sum of the
longest diameters of target lesions by at least 30%. No
growth of nontarget lesions is apparent and no new
lesions have appeared.
Stable disease (SD)
Any response that is not defined as a CR, PR, or
progression.
Progressive disease (PD)
Progressive disease is defined as at least a 20% increase in
the sum of the longest diameters of the target lesions, and/
or appearance of one or more new lesions, and/or
unequivocal progression of existing nontarget lesions.
Failure to return for evaluation due to death or deteriorat-
ing condition (unless clearly unrelated to cancer) will also
be considered progressive disease. Worsening of existing
nonevaluable disease does not constitute progression.
Neoadjuvant chemotherapy will be stopped when disease
progression is observed and subsequent treatment will be
administered as described.BMC Cancer 2004, 4:32 http://www.biomedcentral.com/1471-2407/4/32
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Inoperable disease
Disease may become inoperable following preoperative
chemotherapy due to the development of medical con-
traindications or because of progression of disease. Fur-
ther therapy for patients with inoperable disease due to
the development of medical contraindications will be at
the discretion of the investigator. Inoperability secondary
to progression of disease will be determined by the sur-
geon using preoperative radiographic studies or while in
the operating room.
Other definitions pertaining to outcome
Duration of response
The interval from the first observation of a response to the
first observation of progressive disease, or to death due to
any cause, or to the time of early discontinuation of treat-
ment due to progressive disease.
Time to progression
Interval from the start of the preoperative study drug to
the first evidence of progression.
Disease-free survival
Interval between complete surgical ablation and evidence
of recurrence as seen clinically or radiologically. For the
determination overall DFS, an event is defined as the first
occurrence of one of the following: inoperable disease;
residual disease following surgery; local, regional or dis-
tant recurrence of tumor; second primary cancer; or death
from any cause other than cancer. Elevation of tumor
markers does not define a recurrence. Location and extent
of recurrence will be recorded.
Local recurrence
Defined as evidence of tumor in the liver as determined by
needle biopsy, surgical specimen or autopsy. Further treat-
ment of local recurrence will be at the discretion of the
investigator.
Regional recurrence
Defined as the development of tumor in the liver, extend-
ing to locoregional lymph nodes and/or contiguous struc-
tures such as the diaphragm, colon, and extrahepatic
vascular structures. Diagnosis must be confirmed by nee-
dle biopsy or by radiographic documentation that the
mass lesion is increasing in size in the absence of treat-
ment. Further treatment of regional recurrence will be at
the discretion of the investigator.
Distant recurrence
Defined as development of tumor at sites distant to the
liver. Diagnosis must be confirmed by needle biopsy or
autopsy or by radiographic documentation that the mass
lesion is increasing in size in the absence of treatment.
Further treatment of regional recurrence will be at the dis-
cretion of the investigator.
Survival
Interval from the date of liver biopsy to the date of death,
regardless of cause. Cause of death will be recorded.
Statistics and data analysis
Analytical plans
All analyses will be made on an intent-to-treat basis,
which will include all patients who received the first dose
of the neoadjuvant chemotherapy.
Study conduct and patient disposition
The number of patients completing the planned visits dur-
ing the study will be described. Patients who discontinue
study drug or are removed from the study prematurely
will also be reported. Enrollment (treatment) errors, rea-
sons for study discontinuation and time of withdrawal
from the study will be described.
Pretreatment evaluations and baseline characteristics
Patient baseline characteristics will be summarized. Fre-
quency tables will be presented for categorical variables
and descriptive statistics will be utilized to summarize
continuous variables.
Treatment administration
Study drug administration will be described in terms of
the total number of cycles administered (neoadjuvant and
adjuvant); dose intensity; relative dose intensity; dose
modifications, dose delays, and dose omissions.
Efficacy analyses
The overall response rate (with 95% confidence interval)
will be presented. The influence of baseline patient char-
acteristics on this outcome will be explored using logisti-
cal regression procedures. Analyses of other outcomes (eg:
hepatic disease-free survival, time to progression, overall
survival, resectability rate, surgical complications, etc.)
will also be conducted. For time-to-event data, Kaplan-
Meier procedures will be used.
Table 2: Stopping criteria.
N # Nonresectable
10 5
15 7
20 9
25 10BMC Cancer 2004, 4:32 http://www.biomedcentral.com/1471-2407/4/32
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Safety analyses
Safety Analyses will include an analysis of all adverse
events. All subjects enrolled in the study who received at
least one dose of study medication will be included in the
safety analyses.
Determination of sample size
The number of patients to be studied should demonstrate
a difference in 2-year disease-free survival of 25%, given
an estimated 3-year disease-free survival in the absence of
this regimen of 40% (ie: Po), with an alpha of 0.05 and a
power of 0.8, by a 2-tailed test. It is estimated that 70
patients will be required to demonstrate such a difference.
It is estimated that 25 – 30 patients will be accrued per
year and the study will therefore require 2 – 3 years to
complete accrual.
Stopping rules/discontinuation criteria
The study will be stopped if ever convincing evidence is
generated that nonresectability after the neoadjuvant
chemotherapy is >20% (which is an estimate of the non-
resectability rate in the absence of neoadjuvant therapy).
The decision rule is based on Table 1, which depicts the
number of patients that would have to be found to have
unresectable disease, given a certain number patients who
have received the therapy (with 95% confidence inter-
vals). For example, once 10 patients have been accrued, if
5 patients have been found at the time of operation to
have unresectable disease, then the study will be stopped.
Ethics
The trial will be performed in accordance with the recom-
mendations guiding physicians in biomedical research
involving human patients adopted by the 18th World
Medical Assembly, Helsinki, Finland, 1964 and later revi-
sions. The trial has been approved by the Conjoint Health
Research Ethics Board at the University of Calgary. As the
trial expands to involve other centers, local ethics commit-
tee approvals will similarly be required.
Discussion
Most reports on neoadjuvant chemotherapy for liver
metastases focus on the utility of the strategy in the con-
text of unresectable disease [16,17,20]. In this context,
metastases can sometimes be converted to a resectable
state. There are a number of theoretical advantages to
administering neoadjuvant chemotherapy in the context
of resectable disease. On the other hand, these postulated
advantages must be balanced against the risk of disease
progression, as surgery is delayed for systemic chemother-
apy. Disease progression may be an adverse outcome of
the protocol, but it could also be viewed as a positive
selective influence. That is, if intrahepatic disease
progresses to a point where resection is no longer an
option, then preoperative chemotherapy has not served
the patient well. In contrast, if an extrahepatic focus of dis-
ease appears while on chemotherapy, then the interval of
observation was useful in averting an unnecessary metas-
tasectomy. An additional potential risk of the protocol is
that of postoperative liver dysfunction, as chemotherapy
is known to be associated with steatosis. It is these safety
issues that this phase II protocol is designed to address.
At the time of submission of this protocol for publication,
the study is already in progress. So far, 22 patients have
been accrued and none of the criteria for discontinuation
of the study have been reached. Some changes to the pro-
tocol are anticipated, but still require regulatory and ethi-
cal review. In particular, the upper limit of the age
inclusion criteria will be eliminated (so all patients aged
18 years and older will be allowed to participate), In addi-
tion, we will include patients who have received adjuvant
chemotherapy for their primary tumor if given 6 months
or more prior to enrollment (as opposed to 12 months).
These revisions to the inclusion criteria were made
because it was thought that there was a reasonable chance
of benefit from the protocol, in patients with the revised
criteria.
At present, two centers (Calgary and Edmonton) are
actively accruing. A number of other Canadian centers
have been invited to participate, in hopes that the rate of
accrual will accelerate. This will also serve to expose other
centers to this unconventional method of treating resecta-
ble liver metastases, facilitating further studies in the
future. The data derived from this study will be used to
decide whether to proceed with a phase III study, perhaps
comparing patients treated with this perioperative
approach to patients treated with postoperative chemo-
therapy alone.
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